^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SSBP2 (Single Stranded DNA Binding Protein 2)

    i
    Other names: SSBP2, Single Stranded DNA Binding Protein 2, Single-Stranded DNA-Binding Protein 2, Sequence-Specific Single-Stranded-DNA-Binding Protein 2, Single-Stranded DNA Binding Protein 2, HSPC116, SOSS-B2, SSDP2
    3ms
    Adverse reactions of dasatinib in pediatric acute lymphoblastic leukemia: a retrospective comparative cohort study. (PubMed, Transl Pediatr)
    These findings underscore the necessity for vigilant, protocol-driven monitoring of blood counts and cardiac function (including echocardiography) during dasatinib therapy. Proactive management strategies should be considered to mitigate these risks and improve treatment safety.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • JAK1 (Janus Kinase 1) • CSF1R (Colony stimulating factor 1 receptor) • SSBP2 (Single Stranded DNA Binding Protein 2)
    |
    TP53 mutation
    |
    dasatinib
    3ms
    Identification of radiotherapy-sensitive genes for predicting prognosis, immune microenvironment, and drug sensitivity in uterine carcinosarcoma patients. (PubMed, Medicine (Baltimore))
    We have developed a scoring method for uterine carcinosarcoma based on the effectiveness of radiotherapy. This method can evaluate the prognosis of patients with uterine carcinosarcoma and has certain guiding significance for the clinical treatment of subsequent uterine carcinosarcoma patients.
    Journal
    |
    SSBP2 (Single Stranded DNA Binding Protein 2)
    5ms
    Transcription factor MYB regulates glycolysis to promote the transfer and malignant progression of gastric cancer through the SSBP2/ISL1 axis. (PubMed, Cancer Cell Int)
    MYB mediates glycolysis and malignant progression in GC cells through regulation of the SSBP2/ISL1 axis.
    Journal
    |
    RPA1 (Replication Protein A1) • SSBP2 (Single Stranded DNA Binding Protein 2) • ISL1 (ISL LIM Homeobox 1)
    over1year
    Targeting the ZMIZ1-Notch1 signaling axis for the treatment of tongue squamous cell carcinoma. (PubMed, Sci Rep)
    In vitro and in vivo data suggest that knock down of ZMIZ1 may inhibit TSCC invasion and metastasis by modulating Notch signaling. ZMIZ1 inhibition may therefore represent a new therapeutic target for TSCC.
    Journal
    |
    NOTCH1 (Notch 1) • PIAS4 (Protein Inhibitor Of Activated STAT 4) • SSBP2 (Single Stranded DNA Binding Protein 2) • MMP7 (Matrix metallopeptidase 7)
    2years
    Genetic and Cytometric Characteristics of Pediatric B-Other Acute Lymphoblastic Leukemia Cohort (ASH 2023)
    "Our study shows population-based frequencies of novel ALL subtypes, including both recurrent and novel genetic aberrations. This data widens our knowledge on the interplay between molecular aberrations and clinical course of the disease and provides clues for diagnostics optimization."
    Clinical
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • RUNX1 (RUNX Family Transcription Factor 1) • CD74 (CD74 Molecule) • KMT2A (Lysine Methyltransferase 2A) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • PAX5 (Paired Box 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL7R (Interleukin 7 Receptor) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • CD99 (CD99 Molecule) • SSBP2 (Single Stranded DNA Binding Protein 2) • BLNK (B Cell Linker)
    |
    FGFR1 fusion • MLL fusion
    |
    FusionPlex® Dx
    2years
    The Use of Targeted RNA- Sequencing Assay in the Diagnostic Evaluation of Acute Myeloid Leukaemia(AML) (ASH 2023)
    "The ability to risk-stratify newly diagnosed AML patients allows earlier initiation of targeted therapies. We found that targeted RNA-sequencing (Archer Fusion Plex) is sensitive and showed 100% concordance in identifying fusions associated with good cytogenetic risk AML. Targeted RNA-sequencing can also identify high risk fusion genes such as NUP98-NSD1 for which FISH fusion probes are not routinely used."
    JAK2 (Janus kinase 2) • ETV6 (ETS Variant Transcription Factor 6) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • SSBP2 (Single Stranded DNA Binding Protein 2) • ADGRG7 (Adhesion G Protein-Coupled Receptor G7)
    |
    FusionPlex™ Pan-Heme panel
    2years
    Pediatric Patients with Acute Lymphoblastic Leukemia Treated with Blinatumomab in a Real-World Study (ASH 2023)
    The patients received a 7-day pre-treatment VCP regimen consisting of intravenous infusions of cyclophosphamide 800 mg/m 2 on day 1, vindesine 3 mg/m 2 on day 1, prednisone 1-2 mg/kg on days 1 to 7 (VCP regimen), followed by 28 days of treatment with blinatumomab at 5µg/m 2/day on the first 1 to 7 days and 15 µg/m 2/day on the next 8 to 28 days...Blinatumomab was administered to 5 patients in the induction remission period, and for 2 patients, blinatumomab was administered in consolidation after inotuzumab ozogamicin (INO)...Blinatumomab consolidation therapy was also effective in patients pretreated with INO. Blinatumomab consolidation after induction therapy could be a new and effective strategy for the treatment of patients with newly diagnosed B-ALL.
    Clinical • Real-world evidence • Real-world
    |
    CRLF2 (Cytokine Receptor Like Factor 2) • PBX1 (PBX Homeobox 1) • CSF1R (Colony stimulating factor 1 receptor) • SSBP2 (Single Stranded DNA Binding Protein 2)
    |
    cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • prednisone • vindesine
    over2years
    Nanopore Cas9-Targeted Long-Read Sequencing - a Fast and Flexible Diagnostic Tool for the Identification of B-Cell Acute Lymphoblastic Leukemia Associated Gene Rearrangements (ASH 2023)
    In conclusion, our newly developed targeted sequencing panel correctly identified 96.3% (26/27) analyzed gene rearrangements in B-ALL, including alterations evading standard diagnostic methodologies such as IGH::DUX4 or IGH::EPOR. Importantly, the assay allows individual analysis in a single sample format, thereby representing a valuable tool for B-ALL diagnostics in small to medium-sized laboratories.
    IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • PAX5 (Paired Box 5) • AFF1 (AF4/FMR2 Family Member 1) • EP300 (E1A binding protein p300) • P2RY8 (P2Y Receptor Family Member 8) • CSF1R (Colony stimulating factor 1 receptor) • EBF1 (EBF Transcription Factor 1) • MEF2D (Myocyte Enhancer Factor 2D) • SSBP2 (Single Stranded DNA Binding Protein 2) • BCL9 (BCL9 Transcription Coactivator) • DUX4 (Double Homeobox 4) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor) • ZNF384 (Zinc Finger Protein 384)
    |
    MYC translocation • MEF2D-CSF1R fusion
    over2years
    Immunohistochemical Analysis of Single-Stranded DNA Binding Protein 2 in Non-Melanoma Skin Cancers. (PubMed, Biomedicines)
    SSBP2 evaluation using IHC can be helpful in the differential diagnosis of SCC and BCC. SSBP2 expression was associated with tumor invasiveness in SCC.
    Journal
    |
    RPA1 (Replication Protein A1) • SSBP2 (Single Stranded DNA Binding Protein 2)
    over2years
    Structural basis of the interaction between BCL9-Pygo and LDB-SSBP complexes in assembling the Wnt enhanceosome. (PubMed, Nat Commun)
    These interactions critically depend on the NPF motifs which bind to a deep groove formed between LDB1 and SSBP2, potentially constituting a binding site for drugs blocking Wnt/β-catenin signaling. Analysis of human cell lines lacking LDB or Pygo supports the functional relevance of the Pygo-LDB1-SSBP2 interaction for Wnt/β-catenin-dependent transcription.
    Journal
    |
    RPA1 (Replication Protein A1) • SSBP2 (Single Stranded DNA Binding Protein 2) • BCL9 (BCL9 Transcription Coactivator)
    almost3years
    GENETIC CHARACTERISTICS OF PEDIATRIC B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA COHORT USING TARGETED RNA SEQUENCING (EHA 2023)
    Our study shows population-based frequencies of novel ALL subtypes, including both recurrent and novel geneticaberrations. This data widens our knowledge on the interplay between molecular aberrations and clinical course of the disease and provides clues for diagnostics optimization.
    Clinical
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • FGFR1 (Fibroblast growth factor receptor 1) • RUNX1 (RUNX Family Transcription Factor 1) • CD74 (CD74 Molecule) • KMT2A (Lysine Methyltransferase 2A) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • SSBP2 (Single Stranded DNA Binding Protein 2)
    |
    FGFR1 fusion • MLL fusion
    over3years
    A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations (ASH 2022)
    Patients with Ph-like ALL harboring JAK2 or EPOR rearrangements or IL7R indels routinely had higher LDA scores and levels of EOI MRD positivity versus those with the more common CRLF2-R subtype (Tasian ASH 2020 #1095). JAK2 rearrangements occurred most frequently amongst Cohort C patients, often with previously-unknown gene partners. Although 13/23 (56.5%) of Cohort C patients were EOC MRD+, most patients demonstrated a marked decrement in EOI to EOC MRD with ruxolitinib and consolidation chemotherapy.
    Clinical • P2 data • Minimal residual disease
    |
    CRLF2 (Cytokine Receptor Like Factor 2) • PAX5 (Paired Box 5) • IL7R (Interleukin 7 Receptor) • EBF1 (EBF Transcription Factor 1) • SH2B3 (SH2B Adaptor Protein 3) • DCT (Dopachrome Tautomerase) • SSBP2 (Single Stranded DNA Binding Protein 2)
    |
    CRLF2 rearrangement • JAK2 mutation • EPOR rearrangement • JAK2 fusion • JAK2 rearrangement • SH2B3 deletion
    |
    Jakafi (ruxolitinib)